Publications

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362. PMID: 32341772.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al.  Consequences of increasing mt-sDNA utilization among colorectal cancer screening strategies from a payer perspective. American Society of Preventative Oncology 44th Annual ASPO Conference, 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Health and economic implications for integrated delivery networks of increasing mt-sDNA utilization among colorectal cancer screeners. American Society of Preventative Oncology 44th Annual ASPO Conference, 2020.

Hathway J, Jensen IS, Cyr PL, Koshy, TI, Parks, P, Weinstein MC. Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: Key components to improve practical applications in the US. ISPOR 24th Annual International Meeting, New Orleans LA, 2019.

Malone D, Miller B, Dean R, Arjunji R, Jensen IS, Maru B, Dabbous O. 2019. Abstract PRO10: Use of single dose gene-replacement therapy for the treatment of spinal muscular atrophy type 1: A United States payer budget impact analysis. Value in Health 22(Sup2):S336-S337; doi: 10.1016/j.jval.2019.04.1644.

Malone DC, Dean R, Miller B, Arjunji R, Feltner DE, Sproule D, Jensen IS, Maru B, Dabbous O. 2019. Abstract ND2: Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment. Value in Health 22(Sup 2):S42-S43; doi: 10.1016/j.jval.2019.04.060.

Arjunji R, Dean R, Jensen IS, Miller B, Menier M, Sproule DM, Feltner DE, Droege M, et al. 2019. Abstract PBI10: Type I spinal muscular atrophy patients treated with AVXS-101 have lower use of ventilatory support, hospitalization, and associated costs compared to those treated with nusinersen. Value in Health 22(Sup 2):S48; doi: 10.1016/j.jval.2019.04.093.

Malone DC, Dean R, Arjunji R, Jensen IS, Cyr PL, Miller B, Maru B, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):1601484; doi: 10.1080/20016689.2019. PMID: 31105909.

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salhuddin K, Prats J, et al. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention (PCI) patients: A US hospital perspective. Transcatheter Cardiovascular Therapeutics (TCT), San Diego, CA, 2018.

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL). European Blood and Marrow Transplantation Meeting, Lisbon Portugal, 2018.

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of axicabtagene ciloleucel (Axi-cel) in an US population of patients with relapsed or refractory large b-cell lymphoma (RR-LBCL). Podium presentation at ISPOR 23th Annual International Meeting, Baltimore MD, 2018.

Jensen I, Zacherle E, Noone J, Blanchette C, Kay C. Estimating the life-time indirect costs of vision impairment (VI) in inherited retinal degeneration (IRD): Economic impact on education, government benefit programs, productivity and tax loss for patients and caregiver burden. Presented at AAO 2018.

Jensen IS, Wu E, Sacks N, Cyr P, Chung K. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective. Abstract 5615, 59th American Society of Hematology (ASH) Annual Meeting. Blood 130(Sup 1):5615; 10.1182/blood.V130.Suppl_1.5615.5615. Atlanta, GA, December 2017.

Wu E, Jensen IS, Cyr PL, Kisner H. Economic model shows that guideline recommended testing of patients with early symptoms of myeloma results in improved patient outcomes and decreased hospital costs. American Society of Hematology, Atlanta GA, 2017.

Jensen IS, Wu E, Cyr PL, Gauden D. Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer. ISPOR 16th Annual European Congress, Glasgow, Scotland, 2017.

Berger K, Rossi G, Orlando V, Fabry P, Jensen IS, Gallacher ME, et al. Mobilizing stem cells with plerixafor in MM patients: Impact on a health care provider’s budget in Germany and Italy. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 2017.

Jensen I, Zacherle E, Blanchette C, Zhang J, Yin W. 2016. Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context 5(Jul 15):212297; doi: 10.7573/dic.212297. PMID: 27540409.

Jensen IS, Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL, et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752. PMID: 27231802.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8. PMID: 26692006.